BRPI0417192A - composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4 - Google Patents

composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4

Info

Publication number
BRPI0417192A
BRPI0417192A BRPI0417192-6A BRPI0417192A BRPI0417192A BR PI0417192 A BRPI0417192 A BR PI0417192A BR PI0417192 A BRPI0417192 A BR PI0417192A BR PI0417192 A BRPI0417192 A BR PI0417192A
Authority
BR
Brazil
Prior art keywords
toll
receptor
receptor agonist
agonist
immunostimulatory composition
Prior art date
Application number
BRPI0417192-6A
Other languages
English (en)
Inventor
Nicolas Burdin
Jean Haensler
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BRPI0417192A publication Critical patent/BRPI0417192A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSIçãO IMUNOESTIMULANTE, COMPREENDENDO PELO MENOS UM AGONISTA DOS RECEPTORES TOLL-LIKE 7 OU DO RECEPTOR TOLL-LIKE 8 E UM AGONISTA DO RECEPTOR TOLL-LIKE 4". A invenção se refere a uma composição imunoestimulante, compreende pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8, assim como um agonista do receptor toll-like 4. Essa composição pode, além disso compreender um antígeno vacinal.
BRPI0417192-6A 2003-12-19 2004-12-20 composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4 BRPI0417192A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0314995A FR2863890B1 (fr) 2003-12-19 2003-12-19 Composition immunostimulante
PCT/FR2004/003308 WO2005060966A1 (fr) 2003-12-19 2004-12-20 Composition immunostimulante comprenant au moins un agoniste des recepteurs toll-like 7 ou du recepteur toll-like 8 et un agoniste du recepteur toll-like 4

Publications (1)

Publication Number Publication Date
BRPI0417192A true BRPI0417192A (pt) 2007-03-06

Family

ID=34630344

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417192-6A BRPI0417192A (pt) 2003-12-19 2004-12-20 composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4

Country Status (14)

Country Link
US (2) US20070087009A1 (pt)
EP (1) EP1750707B1 (pt)
JP (1) JP2007514725A (pt)
KR (1) KR20060124669A (pt)
CN (1) CN1921862A (pt)
AU (1) AU2004305276B2 (pt)
BR (1) BRPI0417192A (pt)
CA (1) CA2549114C (pt)
FR (1) FR2863890B1 (pt)
IL (1) IL176270A0 (pt)
LV (1) LV13498B (pt)
NO (1) NO20063254L (pt)
WO (1) WO2005060966A1 (pt)
ZA (1) ZA200605250B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006207891C1 (en) 2005-01-28 2011-09-01 Galen Bio, Inc. Immunologically active compositions
WO2006116423A2 (en) * 2005-04-26 2006-11-02 Eisai Co., Ltd Compositions and methods for cancer immunotherapy
ES2577514T3 (es) * 2005-08-22 2016-07-15 The Regents Of The University Of California Antagonistas de TLR
CA2636424A1 (en) * 2006-01-09 2007-10-25 The Regents Of The University Of California Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
CA2653941C (en) 2006-05-31 2013-01-08 The Regents Of The University Of California Substituted amino purine derivatives and uses thereof
AU2008302276B2 (en) 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
KR101515489B1 (ko) 2006-09-29 2015-04-30 다케다 백신즈 인코포레이티드 노로바이러스 백신 제제
SI2510946T1 (sl) * 2007-02-07 2015-12-31 The Regents Of The University Of California Konjugati sintetičnih agonistov TLR in njihove uporabe
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
US20110104293A1 (en) * 2008-07-01 2011-05-05 Bali Pulendran Synergistic induction of humoral and cellular immunity by combinatorial activation of toll-like receptors
SG2013057732A (en) 2008-08-08 2015-02-27 Ligocyte Pharmaceuticals Inc Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
MX2011008500A (es) 2009-02-11 2011-09-26 Univ California Moduladores del receptor tipo toll y tratamiento de enfermedades.
EP2575773A4 (en) * 2010-05-26 2014-06-25 Selecta Biosciences Inc SYNTHETIC NANOTRÄGERKOMBINATIONSIMPFSTOFFE
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
CA3116265A1 (en) 2014-10-07 2016-04-14 Cytlimic Inc. Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell
RU2714117C2 (ru) 2015-03-09 2020-02-11 Ситлимик Инк. Пептид, полученный из gpc3, фармацевтическая композиция для лечения или предотвращения рака с его использованием, индуктор иммунитета и способ получения антиген-презентирующих клеток
EP3797794A1 (en) 2015-04-07 2021-03-31 Cytlimic Inc. Medicine comprising a toll like receptor 3 agonist and a lag-3 protein
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
WO2018070069A1 (ja) 2016-10-11 2018-04-19 サイトリミック株式会社 医薬
US10508115B2 (en) * 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
KR100711561B1 (ko) * 1999-02-01 2007-04-27 에-자이가부시기가이샤 면역학적 보조제 화합물
EP1478371A4 (en) * 2001-10-12 2007-11-07 Univ Iowa Res Found METHODS AND PRODUCTS FOR ENHANCING IMMUNE RESPONSES USING IMIDAZOQUINOLINE COMPOUND
JP2005513021A (ja) * 2001-11-16 2005-05-12 スリーエム イノベイティブ プロパティズ カンパニー Ｉｒｍ化合物およびトール様受容体経路に関する方法および組成物
NZ573064A (en) * 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
US20040248837A1 (en) * 2002-11-01 2004-12-09 Eyal Raz Methods of treating pulmonary fibrotic disorders
JP2006512391A (ja) * 2002-12-30 2006-04-13 スリーエム イノベイティブ プロパティズ カンパニー 組み合わせ免疫賦活薬
WO2005016235A2 (en) * 2003-04-14 2005-02-24 The Regents Of The University Of California Combined use of impdh inhibitors with toll-like receptor agonists
GB0321615D0 (en) * 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물

Also Published As

Publication number Publication date
CA2549114A1 (en) 2005-07-07
JP2007514725A (ja) 2007-06-07
US20100247557A1 (en) 2010-09-30
KR20060124669A (ko) 2006-12-05
AU2004305276B2 (en) 2010-07-01
WO2005060966A1 (fr) 2005-07-07
ZA200605250B (en) 2007-11-28
EP1750707B1 (fr) 2018-03-14
AU2004305276A1 (en) 2005-07-07
CA2549114C (en) 2013-05-14
LV13498B (en) 2007-05-20
FR2863890B1 (fr) 2006-03-24
EP1750707A1 (fr) 2007-02-14
NO20063254L (no) 2006-07-13
IL176270A0 (en) 2006-10-05
US20070087009A1 (en) 2007-04-19
FR2863890A1 (fr) 2005-06-24
CN1921862A (zh) 2007-02-28

Similar Documents

Publication Publication Date Title
BRPI0417192A (pt) composição imunoestimulante, compreendendo pelo menos um agonista dos receptores toll-like 7 ou do receptor toll-like 8 e um agonista do receptor toll-like 4
WO2003031573A3 (en) Toll-like receptor 3 signaling agonists and antagonists
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
EA200702643A1 (ru) Антитела, связывающие tweak
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
NO20092052L (no) Antistoffer og immunkonjugater, og anvendelser derav
IL185871A0 (en) N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
SE0301372D0 (sv) Novel compounds
ATE426412T1 (de) Adjuvante influenza-vakzine
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
BRPI0810332A2 (pt) "politioéter envolvido com amina/hidroxi"
MY183144A (en) Toll-like receptor 3 antagonists
MEP10209A (en) Stable emulsion composition
WO2005087793A3 (en) Immunostimulatory compositions and uses thereof
DE50208842D1 (de) Federelement
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
ZA200604874B (en) Pharmaceutical compositions
ATE392216T1 (de) Mycobakterieller impfstoff
WO2006063028A3 (en) Immunostimulatory compositions and uses thereof
SE0301100D0 (sv) Skadedjursrepellent
DE502004003470D1 (de) Wasserlösliche, fluoreszierende perylentetracarbonsäure bisimide
MX2009003300A (es) Vectores de rhinovirus recombinantes.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2285 DE 21/10/2014.